BioCanada

Found 31,826 articles

• Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

  5/18/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints.

• BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

  5/18/2022

  BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer.

• Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

  5/18/2022

  Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA ® Vascular Closure Device.

• RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

  5/18/2022

  Since the AccumTM molecule was previously shown to significantly enhance the immunogenicity of various proteins, as shown notably in our press releases dated of January 26th, 2022 and November 3rd, 2021, the Defence team engineered a novel protein-based vaccine targeting the oncogenic protein E7 normally used by HPV to transform healthy cells into an outgrowing tumor.

• ScreenPro Provides Update on Concierge Medical Business Operations

  5/18/2022

  The public health care system is facing unprecedented demand with patients routinely waiting over 10 hours in an emergency department for care. In the covid era, primary care is becoming increasingly difficult to access with many doctors seeing patients virtually.

• Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry

  5/18/2022

  Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) is pleased to announce that its CEO, Dr. Roger McIntyre has been invited to speak at the American Psychiatric Association Annual Meeting in New Orleans May 21, 2022.

• Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

  5/18/2022

  Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022.

• Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update

  5/18/2022

  Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2022.

• Newtopia Reports First Quarter 2022 Financial Results

  5/18/2022

  Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled habit change provider focused on preventing, slowing and reversing chronic disease, today announced its first quarter 2022 financial results and operational highlights.

• Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes

  5/17/2022

  Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE (FSE: EVT; NASDAQ: EVO), a global pharmaceutical and life science company, and leading developer of iPSC cell technologies for therapeutic applications, are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes

• Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in Adults

  5/17/2022

  Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary coverage for AJOVY® (fremanezumab) by Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland.

• Slynd® (drospirenone), a new progestin-only contraceptive pill from Duchesnay which offers a 24-hour safe window for a missed pill

  5/17/2022

  A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.

• Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes

  5/17/2022

  Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics announced a partnership in the field of diabetes.

• TULSA-PRO® Was Front and Center at AUA2022

  5/17/2022

  Profound Medical Corp. announced that multiple clinical presentations and product demonstrations performed at the American Urological Association's 2022 Annual Meeting, which took place from May 13 – 16 in New Orleans, highlighted the ability of TULSA-PRO® to effectively and safely ablate physician-prescribed prostate tissue in an unrivaled variety of patients with prostate cancer and benign prostatic hyperplasia.

• Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer

  5/17/2022

  Inversago Pharma Inc., a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer, effective immediately.

• Gemina Labs Announces CE Mark for its First Product - The Best in Class Legio-X COVID Rapid Antigen Test

  5/17/2022

  Gemina Laboratories Ltd. is pleased to announce that its inaugural product - the Gemina Legio XTM COVID-19 Rapid Antigen Test - has been awarded an EU CE Mark under the EU's In Vitro Diagnostic Medical Device Directive.

• StageZero Life Sciences, Ltd Announces Q1 2022 Financial Results and Operational Update

  5/17/2022

  StageZero Life Sciences announced its first quarter financial results for the three months ended March 31, 2022, and provided an update on its business progress.

• Nirvana Signs Letter of Intent with Innovate Phytotechnologies Inc.

  5/17/2022

  Mr. Michael McCune, Nirvana's Vice President of Operations commented, "This is a major step for the Company, the ability to develop and distribute unique products through a Health Canada licensed facility that has full analytical capabilities will allow Nirvana to offer the highest level of quality assurance.

• ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

  5/17/2022

  ProMIS Neurosciences, Inc. announced its participation at the Neuro4D International Conference, held at the Atrium Hotel, Mainz, Germany, May 16-17th.

• Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022

  5/17/2022

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, has filed its financial statements for the quarter ended March 31, 2022, in accordance with applicable Canadian securities laws.